VIP 10mg is a research-grade vasoactive intestinal peptide (VIP) developed for laboratory investigations involving VPAC receptor biology, GPCR signaling, neuropeptide-mediated intracellular communication, receptor pharmacology, and molecular biology. VIP is a naturally occurring 28-amino acid neuropeptide belonging to the secretin/glucagon peptide family and is recognized for its highly conserved structure and broad receptor interactions. Its well-characterized molecular identity has made VIP one of the most extensively investigated endogenous neuropeptides for studying peptide-receptor interactions and intracellular signaling within controlled laboratory environments.
One of the defining characteristics of VIP research is its interaction with the VPAC1 and VPAC2 receptors, members of the class B G protein-coupled receptor (GPCR) family. Researchers investigate ligand affinity, receptor selectivity, receptor activation, intracellular signaling cascades, receptor internalization, and downstream molecular communication to better understand neuropeptide receptor biology. These investigations contribute to expanding scientific understanding of receptor pharmacology while maintaining an exclusive Research Use Only designation.
Scientific investigations also focus extensively on GPCR-mediated intracellular signaling. Laboratory studies evaluate VIP within experimental systems investigating receptor-mediated activation, adenylyl cyclase stimulation, cyclic AMP (cAMP) production, protein kinase A (PKA) activation, intracellular messenger systems, CREB activation, and coordinated molecular communication. Researchers continue exploring these pathways to improve scientific understanding of neuropeptide receptor signaling across diverse biological models.
Another major area of investigation involves neuropeptide communication and peptide-mediated molecular signaling. Researchers investigate VIP within laboratory models examining intracellular communication, receptor specificity, peptide stability, transcriptional regulation, ligand-receptor interactions, and coordinated signaling between neurons and peripheral tissues. These investigations remain centered on molecular biology and receptor pharmacology without implying therapeutic applications.
Current laboratory investigations further evaluate intracellular signaling involving VPAC1, VPAC2, Gs proteins, adenylyl cyclase, cyclic AMP (cAMP), protein kinase A (PKA), CREB, ERK1/2, MAPK signaling, and additional molecular systems associated with neuropeptide receptor activation. Researchers investigate these pathways to better understand receptor biology, intracellular signaling, ligand specificity, peptide pharmacology, and molecular communication.
Comparative neuropeptide research represents another significant area of scientific interest. Researchers frequently compare VIP with PACAP, Oxytocin, Semax, and additional investigational neuropeptides to evaluate receptor selectivity, signaling characteristics, structural biology, intracellular communication, peptide stability, and laboratory applications. Comparative investigations continue expanding scientific understanding of neuropeptide physiology and GPCR-mediated signaling.
The 10mg presentation is particularly appropriate for laboratories conducting receptor biology investigations, neuropeptide signaling studies, molecular pharmacology research, analytical validation, receptor binding experiments, biomarker discovery, peptide characterization, and collaborative scientific research. Although presentation strengths vary, the molecular identity, manufacturing standards, analytical quality controls, and intended laboratory applications remain consistent throughout the VIP product family.
Beyond receptor investigations, VIP serves as an important analytical reference material within peptide chemistry, neuroscience, molecular biology, analytical chemistry, receptor pharmacology, structural biology, assay development, biomarker discovery, cellular physiology, and systems biology. Its reproducible analytical profile makes it valuable for laboratories investigating neuropeptide biology and receptor-mediated intracellular signaling.
Each batch of VIP 10mg is manufactured according to research-grade production standards and undergoes comprehensive analytical verification before release. Quality assurance procedures include High-Performance Liquid Chromatography (HPLC) purity analysis, peptide identity confirmation, amino acid sequence verification, molecular weight characterization, and rigorous batch-specific quality control testing. These analytical measures support reproducibility, consistency, and confidence across independent laboratory investigations.
To preserve molecular integrity, VIP should be stored according to accepted laboratory recommendations for lyophilized peptides. Appropriate storage conditions, controlled handling practices, and adherence to established laboratory protocols help maintain peptide stability before analytical evaluation and experimental preparation.
Although VIP remains one of the most extensively investigated endogenous neuropeptides, ongoing scientific research continues exploring VPAC receptor biology, GPCR signaling, intracellular communication, cAMP signaling, ligand-receptor interactions, and comparative neuropeptide pharmacology. Consequently, VIP 10mg should be regarded exclusively as an investigational research peptide intended to support laboratory research and scientific discovery.
VIP 10mg is supplied exclusively for laboratory research and analytical applications. This product is intended for Research Use Only (RUO) and is not approved for human consumption, therapeutic use, veterinary applications, cosmetic use, or diagnostic purposes.
